There is increased risk for lung transplantation or death among patients with pulmonary arterial hypertension who have long-term exposure to particulate matter. Investigators explored the link between ...

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR ™ (sotatercept-csrk) compared to ...

Guest writer Genesis “Gigi” Gonzalez says that, while living with PH, there are moments when she wants to ask, "Why did this ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Pulmonary thromboendarterectomy is a surgery used to treat chronic thromboembolic pulmonary hypertension. It’s the treatment of choice for this condition. Chronic thromboembolic pulmonary hypertension ...

New research has shown that hypertensive individuals who maintain optimal control of several key health risk factors—such as blood pressure, cholesterol, and lifestyle behaviors—can significantly ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

WINREVAIR significantly reduced the risk of major morbidity and mortality events, the primary endpoint, in adults with PAH (Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality ...